Literature DB >> 18586160

Primary endpoints for randomised trials of cancer therapy.

Jack Cuzick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18586160     DOI： 10.1016/S0140-6736(08)60933-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.

Authors:  Judith-Anne W Chapman; Joseph P Costantino; Bin Dong; Richard G Margolese; Kathleen I Pritchard; Lois E Shepherd; Karen A Gelmon; Norman Wolmark; Michael N Pollak
Journal:  Breast Cancer Res Treat       Date:  2015-08-15       Impact factor: 4.872

2.  Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System.

Authors:  Michael P Lux; Claudia Reichelt; Jon Karnon; Thorsten D Tänzer; Dragan Radosavac; Peter A Fasching; Matthias W Beckmann; Falk C Thiel
Journal:  Breast Care (Basel)       Date:  2011-10-13       Impact factor: 2.860

3.  Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research.

Authors:  Martine Moossdorff; Lori M van Roozendaal; Luc J A Strobbe; Stefan Aebi; David A Cameron; J Michael Dixon; Armando E Giuliano; Bruce G Haffty; Brigid E Hickey; Clifford A Hudis; V Suzanne Klimberg; Bogda Koczwara; Thorsten Kühn; Marc E Lippman; Anthony Lucci; Martine Piccart; Benjamin D Smith; Vivianne C G Tjan-Heijnen; Cornelis J H van de Velde; Kimberly J Van Zee; Jan B Vermorken; Giuseppe Viale; Adri C Voogd; Irene L Wapnir; Julia R White; Marjolein L Smidt
Journal:  J Natl Cancer Inst       Date:  2014-11-07       Impact factor: 13.506

4.  Design and testing for clinical trials faced with misclassified causes of death.

Authors:  Bart Van Rompaye; Els Goetghebeur; Shabbar Jaffar
Journal:  Biostatistics       Date:  2010-03-08       Impact factor: 5.899

Review 5.  Pharmacogenomics of breast cancer therapy: an update.

Authors:  Kelly Westbrook; Vered Stearns
Journal:  Pharmacol Ther       Date:  2013-03-13       Impact factor: 12.310

6.  Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.

Authors:  Judith-Anne W Chapman; Lois E Shepherd; James N Ingle; Hyman B Muss; Kathleen I Pritchard; Karen A Gelmon; Timothy J Whelan; Catherine Elliott; Paul E Goss
Journal:  Breast Cancer Res Treat       Date:  2016-03-23       Impact factor: 4.872

Review 7.  Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer.

Authors:  J Cuzick
Journal:  Ann Oncol       Date:  2015-10-03       Impact factor: 32.976

8.  A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.

Authors:  Ting Bao; Ling Cai; Jon T Giles; Jeff Gould; Karineh Tarpinian; Kelly Betts; Michelle Medeiros; Stacie Jeter; Nancy Tait; Saranya Chumsri; Deborah K Armstrong; Ming Tan; Elizabeth Folkerd; Mitch Dowsett; Harvinder Singh; Kate Tkaczuk; Vered Stearns
Journal:  Breast Cancer Res Treat       Date:  2013-02-08       Impact factor: 4.872

9.  The impacts of public mammography screening on the relationship between socioeconomic status and cancer stage.

Authors:  Søren T Klitkou
Journal:  SSM Popul Health       Date:  2016-08-03

10.  Outcome measures in clinical trials of treatments for acute severe haemorrhage.

Authors:  Amy Brenner; Monica Arribas; Jack Cuzick; Vipul Jairath; Simon Stanworth; Katharine Ker; Haleema Shakur-Still; Ian Roberts
Journal:  Trials       Date:  2018-10-01       Impact factor: 2.279
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.